PPD increases capacity, capabilities at Wisconsin-based GMP lab

By Melissa Fassbender

- Last updated on GMT

The expanded PPD® Laboratories stability operation located at the company’s good manufacturing practices (GMP) lab in Middleton, Wisconsin. (Image: Pharmaceutical Product Development LLC)
The expanded PPD® Laboratories stability operation located at the company’s good manufacturing practices (GMP) lab in Middleton, Wisconsin. (Image: Pharmaceutical Product Development LLC)
PPD has expanded its stability sample storage capacity and capabilities at its Middleton, Wisconsin-based good manufacturing practices (GMP) lab.

The expansion includes a 75% increase in capacity for aliquoting, storage, and worldwide distribution of reference standard materials as PPD looks to meet customer demand, according to the company.

"PPD® Laboratories is seeing growth across all service areas, but particularly those supporting the biopharmaceutical sector​," Darren Jantzi, Executive Director, GMP Lab, PPD®​ Laboratories, told Outsourcing-Pharma.com.

"Companies are continuing to look for ways to manage their fixed costs by utilizing our services that offer flexibility in response to their changing needs for sample storage and distribution​," he added.

Notably, the expansion gives the facility the capacity to be equipped with more than 120 new stability chambers – with the ability to expand to 150,000 cubic feet of chamber space and nearly doubling its storage capacity.

According to PPD, the operation enables the lab to offer “a significant expansion​” of the more than 40 different temperature and humidity set points for routine International Conference on Harmonisation (ICH) stability storage conditions.

The expansion will also increase capacity for customized temperature and humidity, photostability, and shipping (freeze/thaw) studies, in addition to creating additional analytical lab space.

"We anticipate the facility will provide ample capacity for our clients into the next decade​," said Jantzi. "We designed the space with flexibility in mind to enable us to make adjustments to the changing demands of the marketplace​."

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers